Cantor Fitzgerald Starts Neogenomics (NEO) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St set to fall at open as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts NEO Hot Sheet
Price: $16.35 -0.97%
Rating Summary:
15 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 18
Rating Summary:
15 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 18
Join SI Premium – FREE
Cantor Fitzgerald initiated coverage on Neogenomics (NASDAQ: NEO) with an Overweight rating and a price target of $11.00.
For an analyst ratings summary and ratings history on Neogenomics click here. For more ratings news on Neogenomics click here.
Shares of Neogenomics closed at $9.03 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: 'Neogenomics (NEO) Is Winning the Community'
- Deutsche Bank Starts Stevanato Group S.p.A. (STVN) at Hold
- UBS Assumes T. Rowe Price (TROW) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
